Mobile website
Archive > Volume 23 Issue 5 > 2016,23(5):692-697. DOI:10.3872/j.issn.1007-385X.2016.05.018 Prev Next
Clinical Research
Feasibility of nimotuzumab combined with radiotherapy and chemotherapy for long-term in the treatment of patients with local advanced nasopharyngeal carcinoma
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective:To evaluate the efficacy and safety of nimotuzumab combined with intensity-modulated radiotherapy and chemotherapy (IMRT) for long-term in treatment of the patients with local advanced nasopharyngeal carcinoma. Methods: Thirty nine patients who diagnosed as Ⅲ-Ⅳ stages nanopharyngeal carcinoma in the Zhejiang Cancer Hospital during November, 2008 to March, 2014 were analyzed, among them 29 cases are male and 10 cases female, 20 cases are at Ⅲ stage, 14 cases at Ⅳ a stage and 5 cases at Ⅳ b stage. All the patients received a long-term treatment of nimotuzumab (200 mg at a time, one time per week) combined with IMRT for 9-18 weeks. Curative efficacy and toxic side effects of the long-term treatment of nimotuzumab combined with IMRT were observed, as well as the acute and chronic toxic side effects of the patients were analyzed according to the criteria of Radiation Therapy Oncology Group (RTOG). Accumulated survival rates of the patients were calculated and analyzed by Kaplan-Meier method and Log-rank test. Results: With a median follw-up period of 46 months (22-86 months), after the long-term treatment of nimotuzumab combined with IMRT for more then nine months local recurrence free survival rate (LRFS), regional recurrence free survival rate (RRFS), distant metastasis free survival rate (DMFS), progression free survival rate (PFS) and overall survival rate (OS) for three years of all the patients were 92.1%, 89.7%, 82.5%, 77.6% and 86.8% respectively. Univariate analysis showed that clinical stages and cycle of new adjuvant chemotherapy have key effect on the survival rates, DMFS for three years of the patients at Ⅲ stage and Ⅳ stage were 100.0% and 63.2% respectively (P<0.01), LRFS for three years of the patients received the treatment 1-2 cycles and 3-4 cycles 75.0% and 96.8% respectively (P<0.05). Conclusion:The long-term treatment of nimotuzumab combined with intensity-modulated radiotherapy and chemotherapy could improve curative efficacy of the patients with local advanced nasopharyngeal carcinoma, but not increase toxic side effect. However long-term curative efficacy of the treatment might wait on results of follow up for a long period.
Keywords:
Project Supported:
Project supported by the National Natural Science Foundation for Young Scholars of China (No. 81502647)
Clc Number:
